Peptonic Medical AB (publ) (“Peptonic”) announces today changes within its organization. Global Business Director, Erik Sundquist, and Senior Advisor, Dan Markusson, will be leaving their positions in the company.
During his time at Peptonic, Erik Sundquist has played a key role in strengthening the company’s market position and implementing important business strategies. Erik has decided to focus on other professional projects. Dan Markusson, who has held several significant positions within the company, will be leaving Peptonic in mid-June.
“We are grateful for Erik’s and Dan’s efforts and dedication during their time at Peptonic. Their contributions have been significant for the company, and we wish them both the best in their future endeavors,” says Anders Blom, Chairman of the Board of Peptonic Medical AB.
These positions will not be filled at this time.
For further information, please contact:
Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se Phone: +46 70-244 92 07
About Peptonic
Peptonic Medical AB (publ) is a cutting-edge Swedish biomedical company, dedicated in the development and distribution of clinically proven self-care treatments and self-diagnostic tests in intimate women’s health. The portfolio is sold under the brands Vagivital and Vernivia. The company’s vision is to revolutionize intimate health by empowering women to diagnose, treat, and prevent intimate medical conditions independently and effectively.
Central to the growth strategy is the geographical expansion of VagiVital and Verniva through local partners. Peptonic Medical also intends to continuously broaden the company’s product portfolio through acquisitions and the development of innovative and competitive products in-house. The company’s mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio.
The company is headquartered in Stockholm, Sweden, and has subsidiaries Common Sense Marketing Inc in the USA and Peptonic Medical Ltd in Israel. Peptonic Medical was founded in 2009, and the company’s shares have been listed on the Spotlight Stock Market since 2014
